- Home
- VKTX
as 11-15-2024 4:00pm EST
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.2B | IPO Year: | 2015 |
| Target Price: | $109.80 | AVG Volume (30 days): | 6.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.51 - $99.41 | Next Earning Date: | 10-23-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Viking Therapeutics Inc. (VKTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MACARTNEY LAWSON | VKTX | Director | Nov 8 '24 | Sell | $68.67 | 2,000 | $137,333.40 | 47,965 | |
| SINGLETON J MATTHEW | VKTX | Director | Oct 25 '24 | Sell | $79.50 | 16,000 | $1,272,000.00 | 9,500 | |
| Rouan Sarah Kathryn | VKTX | Director | Oct 25 '24 | Sell | $80.89 | 11,000 | $889,790.00 | 0 | |
| Lian Brian | VKTX | President & CEO | Sep 20 '24 | Sell | $71.19 | 216,130 | $15,308,552.90 | 2,305,127 | |
| SINGLETON J MATTHEW | VKTX | Director | Sep 20 '24 | Sell | $69.50 | 10,300 | $715,850.00 | 9,500 | |
| Lian Brian | VKTX | President & CEO | Aug 21 '24 | Sell | $69.90 | 1,000 | $69,900.00 | 2,305,127 | |
| SINGLETON J MATTHEW | VKTX | Director | Aug 21 '24 | Sell | $69.72 | 5,700 | $397,430.22 | 9,500 | |
| Lian Brian | VKTX | President & CEO | Aug 19 '24 | Sell | $66.27 | 112,870 | $7,426,507.68 | 2,305,127 | |
| SINGLETON J MATTHEW | VKTX | Director | Aug 19 '24 | Sell | $62.52 | 16,000 | $995,453.24 | 9,500 |
Latest Viking Therapeutics Inc. News
VKTX Breaking Stock News: Dive into VKTX Ticker-Specific Updates for Smart Investing
Motley Fool
4 hours ago
Is It Too Late to Buy Viking Therapeutics Stock?
Motley Fool
a day ago
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Motley Fool
2 days ago
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Investor's Business Daily
4 days ago
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
Motley Fool
4 days ago
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
PR Newswire
5 days ago
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Motley Fool
7 days ago
Is Viking Therapeutics a Buy on the Dip?
Motley Fool
9 days ago
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
Compare VKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VKTX Viking Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.